Danaher (NYSE:DHR) just took a hit, dropping by 8.6% in the morning, the steepest fall since April 2023. Investors weren't thrilled after the company posted Q4 earnings per share of $2.14, missing Wall Street's $2.16 estimate. Revenue came in at $6.5 billion, slightly ahead of projections, but weak margins and cautious guidance sent the stock sliding. The company expects a low-single digits revenue decline in Q1, implying $5.6 billionbelow analysts' $5.9 billion forecast. While full-year sales are set to rise 3%, investors are questioning whether Danaher can make up for lost ground.
CEO Rainer M. Blair remains optimistic, highlighting strong order trends in bioprocessing and market share gains in molecular diagnostics. But the numbers tell a different storyQ1 2024 revenue was already down 2.5% year-over-year, with core revenue slipping 4%. Looking ahead, management expects Q2 core revenue to drop mid-single digits, with full-year revenue shrinking in the low-single digits. The market, used to Danaher outperforming, isn't reacting well to this softer outlook.
Danaher isn't cheapit trades at 31 times expected 2025 earnings, well above the S&P 500's 22x multiple. Investors expect flawless execution, and the company has historically beaten estimates by nearly 10%. Citi analyst Patrick Donnelly is still bullish with a $285 target but flagged weaker-than-expected growth and margins. With 83% of analysts rating the stock a Buy, confidence is still therebut if Danaher can't turn guidance into growth, investors might start looking elsewhere.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。